BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer's drug

  • 📰 CNBC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 72%

Business News News

Business Business Latest News,Business Business Headlines

Biogen's new Alzheimer's drug aduhelm saw limited pickup in its first few months on the market.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

No wonder….

For all those who are new to this working from home Bitcoin trading options Here's a little tip: Get a trusted Bitcoin expert and stick to him Neal_48 Invest and play at similar times each day. Because : In times of chaos, your investment is your anchor to success

$SAVA coming soon to offer competition

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines